5 Best Pharmaceutical Stocks to Buy for Income

pharma stock

If you’re looking to add some income-generating stocks to your portfolio, the UK pharmaceutical industry is a good place to start.

With a strong track record of financial stability and a steady stream of dividends, these companies are well-suited for investors looking to generate a passive income.

Here are the top five UK pharmaceutical stocks to consider buying for income:

AstraZeneca: This well-established pharmaceutical company has a market capitalisation of £181.49 billion and has consistently outperformed the market. In addition to its strong financial performance, AstraZeneca has a long history of paying dividends, with a current annual dividend yield of around 1.9%. The company has a diverse product portfolio that includes both branded and generic drugs, which helps to mitigate the risk of relying on a single product or therapy area. AstraZeneca has a strong focus on research and development and has a robust pipeline of potential new drugs in various stages of development, which bodes well for its future growth.

GlaxoSmithKline: With a market capitalisation of £58.71 billion, GSK is another well-established biotech company that has a strong track record of financial stability and dividend payments. The company has a current dividend yield of around 6.97% and has consistently paid dividends for over a long period of time. GSK has a diversified product portfolio that includes both prescription and over-the-counter drugs, as well as consumer health products, which helps to mitigate the risk of relying on a single product or therapy area. In addition, the company has a robust pipeline of potential new drugs in development, which bodes well for its future growth.

Novo Nordisk: This Danish pharmaceutical company has a market capitalisation of £84.44 billion and is a leader in the diabetes care market. Novo Nordisk has a long history of paying dividends and currently has a dividend yield of around 0.59% as of January 2023. The company has a diversified product portfolio and a strong focus on research and development, which has helped it to consistently bring new and innovative products to market. In addition, Novo Nordisk has a strong track record of financial stability and is expected to continue paying dividends in the future.

Roche: This Swiss pharmaceutical company has a market capitalisation of £247.41 billion and is a leader in the cancer treatment market. Roche has a strong track record of financial stability and has consistently paid dividends, with a current dividend yield of around 2.2%. The company has a diversified product portfolio that includes both pharmaceuticals and diagnostics, which helps to mitigate the risk of relying on a single product or therapy area. In addition, Roche has a strong focus on research and development and has a robust pipeline of potential new drugs in various stages of development, which bodes well for its future growth.

Celadon Pharmaceuticals PLC: This UK-based pharmaceutical company was founded in 2018 after cannabis-based medicinal products (CBMPs) were legalised in the UK, and the company went public on the London Stock Exchange in 2022. Celadon Pharmaceuticals Plc has a market capitalisation of £31.45 million and is focused on improving patients’ quality of life through the use of CBMPs. Celadon is uniquely positioned as a vertically integrated pharmaceutical company to deliver its patient-first mission. The company has developed its MHRA-approved chronic pain trial to create a robust data set to support reimbursement on the National Health Service in the UK. MOree can

Overall, these are five of the best UK pharmaceutical stocks to consider buying for income. Whether you’re looking for established blue-chip companies or newer biotech firms with strong growth potential, these stocks offer a combination of financial stability, dividend payments, and potential for future growth.

The views expressed in this article are those of the authors and do not necessarily reflect the views or policies of The World Financial Review.